Promentis Pharmaceuticals

MILWAUKEE, WI · Founded 2007 · Biotech · Private

Small molecule therapeutics for neuropsychiatric disorders

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · promentispharma.com

Sector: Biotech
Headquarters: MILWAUKEE, WI
Founded: 2007
Latest Form D: $2.5M, Dec 2019
Total capital: $32.4M

Federal grants: $303K; 2 awards · 2015; Rank in peer group#385 of 392
Private capital raised: $32.1M; 6 Form D · last Dec 2019; 82 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 6; 15 pending · first 2015; Rank in peer group#20 of 392

Capital timeline

Latest events

Dec 2019Private capital raisedForm D · SEC · 6th filing$2.5M
Sep 2017Private capital raisedForm D · SEC · 5th filing$17.6M
Oct 2016Private capital raisedForm D · SEC · 4th filing$8.8M
Sep 2015Federal grantHealth and Human S · Phase I · Targeting System Xc- for the treatment of the Autism Spectrum Disorder subpopulations, Fragile X syndrome and Phelan-McDermid syndrome$151K
Sep 2015Federal grantHealth and Human S · Phase I · Targeting System Xc- for the treatment of the Autism Spectrum Disorder subpopulations, Fragile X syndrome and Phelan-McDermid syndrome$151K
Jan 2014Private capital raisedForm D · SEC · 3rd filing$820K
Apr 2013Private capital raisedForm D · SEC · 2nd filing$750K
Aug 2009Private capital raisedForm D · SEC · 1st filing$1.7M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 392 peers

Line = median

Biotech · Molecule

Federal grantsBelow median
Granted patents#20 · top 5%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Chad BeyerResearcherExecutive OfficerLinked by $151K in grants as PI
Chad E Beyer, PhDExecutive Officer, DirectorNamed in SEC Form D filings
Daniel LawtonExecutive Officer, DirectorNamed in SEC Form D filings
David E Baker, PhDDirectorNamed in SEC Form D filings
Ed BarthellDirectorNamed in SEC Form D filings
Ed E Barthell, MDDirectorNamed in SEC Form D filings

Show all 15 people

Klaus VeitingerDirectorNamed in SEC Form D filings
Klaus E Veitinger, MD, PhDDirectorNamed in SEC Form D filings
Patrick E Schwarz-SchuetteDirectorNamed in SEC Form D filings
Stacey SeltzerDirectorNamed in SEC Form D filings
Steve SquintoDirectorNamed in SEC Form D filings
Thomas BeckDirectorNamed in SEC Form D filings
Thomas A. ShannonDirectorNamed in SEC Form D filings
Tom BeckExecutive Officer, DirectorNamed in SEC Form D filings
Virinder A. Nohria, PhDDirectorNamed in SEC Form D filings

What it has protected

USPTO · 6 granted of 21

Feb 22, 2024PendingSubstituted N-acetyl-l-cysteine Derivatives And Related CompoundsUSPTOApplication 18488215
Dec 23, 2021PendingSubstituted N-acetyl-l-cysteine Derivatives And Related CompoundsUSPTOApplication 17216285
Mar 30, 2021GrantedSubstituted N-acetyl-l-cysteine Derivatives And Related CompoundsUSPTOUS 10,961,187

Show all 21 patent records

Substituted N-acetyl-l-cysteine Derivatives And Related CompoundsFeb 22, 2024 · Application 18488215Pending
Substituted N-acetyl-l-cysteine Derivatives And Related CompoundsDec 23, 2021 · Application 17216285Pending
Substituted N-acetyl-l-cysteine Derivatives And Related CompoundsMar 30, 2021 · US 10,961,187Granted
Substituted N-acetyl-l-cysteine Derivatives And Related CompoundsJul 23, 2019 · US 10,358,414Granted
Substituted N-acetyl-l-cysteine Derivatives And Related CompoundsOct 30, 2018 · US 10,112,897Granted
Substituted N-acetyl-l-cysteine Derivatives And Related CompoundsApr 25, 2017 · US 9,630,937Granted
Cysteine ProdrugsOct 6, 2016 · Application 15174410Pending
Propionic Acids, Propionic Acid Esters, And Related CompoundsNov 24, 2015 · US 9,193,681Granted
Ethyl (2R)-2-ACETAMIDO-3-(4-METHYLBENZOYLSULFANYL)PROPANOATE And Uses ThereofApr 21, 2015 · US 9,012,674Granted
Use of Compounds Elevating Glutathione Levels for the Treatment of Autism, Autistic Spectrum Disorders and Fragile X SyndromeFeb 12, 2015 · Application 14456834Pending
S-t-BUTYL PROTECTED CYSTEINE DI-PEPTIDE ANALOGS AND RELATED COMPOUNDSMay 1, 2014 · Application 14147904Pending
Use of Compounds Elevating Glutathione Levels for the Treatment of Parkinson's DiseaseDec 19, 2013 · Application 13919768Pending
Propionic Acids, Propionic Acid Esters, And Related CompoundsApplication PCTUS2011027476Pending
(R)-ethyl-2-acetamido-3-(((S)-2-amino-3-methylbutanoyl)thio)propanoate and Uses ThereofApplication 62005762Pending
Substituted N-acetyl-l-cysteine Derivatives And Related CompoundsApplication 61902669Pending
Substituted N-acetyl-l-cysteine Derivatives And Related CompoundsApplication 61902052Pending
The Use Of Compounds Elevating Glutathione Levels For The Treatment Of Parkinson's DiseaseApplication PCTUS2013046159Pending
Cysteine ProdrugsApplication PCTUS2012048820Pending
S-protected Cysteine Analogs And Related CompoundsApplication PCTUS2011060444Pending
S-t-butyl Protected Cysteine Di-peptide Analogs And Related CompoundsApplication PCTUS2011060432Pending
Cysteine ProdrugsApplication 61512751Pending

GID BIO, Inc.Similar federal contract value in Biotech · null in contracts
AXILEA LLCSimilar federal contract value in Biotech · null in contracts
Otzi Bio LLCSimilar federal contract value in Biotech · null in contracts
SABER THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
BESSOR PHARMA, LLCSimilar federal contract value in Biotech · null in contracts
ONCOSTING LLCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.